GLP-1 drugs are the biggest medical story of the decade. But which one works best? We compared the clinical trial data.
I was surprised by some of these findings when I first dug into the research.
Head-to-Head Results
| Ozempic | Wegovy | Mounjaro | |
|---|---|---|---|
| Drug class | GLP-1 | GLP-1 (higher dose) | GLP-1 + GIP |
| Weight loss (trial avg) | 10-12% | 15-17% | 20-22% |
| FDA indication | Diabetes | Obesity | Diabetes + Obesity |
| Monthly cost (US) | $900-1,200 | $1,300-1,700 | $1,000-1,500 |
| Nausea rate | 20% | 25% | 15-20% |
| Injection | Weekly | Weekly | Weekly |
The Clear Winner on Weight Loss
Mounjaro (tirzepatide) wins on raw weight loss numbers. The SURMOUNT trials showed 20-22% body weight loss at maximum dose vs 15-17% for Wegovy. The dual GLP-1/GIP mechanism appears genuinely superior.
Related: evidence-based supplement guide
I think the most underrated aspect here is
But Weight Loss Is Not the Whole Story
- Cardiovascular benefit: Ozempic/Wegovy (semaglutide) has the SELECT trial showing 20% reduction in major cardiac events. Mounjaro data is still pending.
- Muscle loss: All GLP-1s cause 25-40% lean mass loss alongside fat loss. Resistance training + high protein (1.2g/kg+) is essential on any of these drugs.
- Regain: 67% of lost weight returns within 1 year of stopping. These are likely lifelong medications.
Have you ever wondered why this matters so much?
Last updated: 2026-04-03
Your Next Steps
- Today: Pick one idea from this article and try it before bed tonight.
- This week: Track your results for 5 days — even a simple notes app works.
- Next 30 days: Review what worked, drop what didn’t, and build your personal system.
Disclaimer: This article is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with any questions about a medical condition.
About the Author
Written by the Rational Growth editorial team. Our health and psychology content is informed by peer-reviewed research, clinical guidelines, and real-world experience. We follow strict editorial standards and cite primary sources throughout.
References
- Jastreboff, A. M., et al. (2022). SURMOUNT-1 trial. NEJM.
- Lincoff, A. M., et al. (2023). SELECT trial. NEJM.
